AI
OpenAI researcher Miles Wang is in talks to start a drug discovery venture with a 2 billion dollar valuation
TechCrunch
Key Points
- OpenAI researcher Miles Wang plans to establish an AI-driven drug discovery venture.
- The target valuation of the new venture to be established stands out as 2 billion dollars.
- It is reported that the venture capital firm Lightspeed is holding talks to lead the investment round.
By the Numbers
2 billion dollar valuation
OpenAI researcher Miles Wang is reported to be launching a new venture focusing on AI-driven drug discovery. The new company is rumored to have a pre-money valuation of 2 billion dollars.
Sources state that Lightspeed Ventures is in talks with the company to lead this funding round. The development shows that investments in the practical applications of artificial intelligence technologies in the pharmaceutical and healthcare sectors continue to gain momentum.
React to this story
Ask about this story
Answers are AI-generated from this story only.
Frequently Asked Questions
- In which field will the venture Miles Wang plans to establish operate?
- The new venture is planned to focus on drug discovery and development processes using artificial intelligence technologies.
- What is the target market valuation of the company?
- According to the information obtained, the startup's valuation is expected to reach 2 billion dollars following the funding round.
- Which organization is being discussed to lead the investment round?
- It is stated that the venture capital firm named Lightspeed is in discussions with the company to spearhead this funding round.
This is an AI-generated summary. The full story lives at the source.
Read the full story at the sourcetechcrunch.comThis story across sources · 2 · 2 countries
ATnl
- Der Brutkasten·
- Silicon Canals·
Related stories
AI